Drug Approval | July 26, 2024
European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
